NewAmsterdam Pharma Company N.V. research snapshot
NAMS AI stock analysis currently reads NewAmsterdam Pharma as a pre-commercial clinical-stage biotechnology company developing obicetrapib, a CETP inhibitor for cardiovascular disease, with a positive European CHMP opinion received on July 24, 2026. At the August 3, 2026 cutoff, the latest verified intraday price was $27.11, market capitalization was about $3.17 billion, and the stock was trading below both its 50-day and 200-day moving averages after pulling back from the $42 area. The main question is whether a potential European Commission marketing authorization in the second half of 2026, a US regulatory path, and the PREVAIL outcomes trial can justify the current valuation. This is informational research and not investment advice.
Current price
$27.11
Market cap
$3.17 billion
AI score
44 / 100
Rating
Pre-commercial biotech, regulatory catalysts ahead
Trend status
Downtrend below key moving averages after a pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | NewAmsterdam Pharma has no approved product and only limited supply-agreement revenue. Its sole focus is obicetrapib, a CETP inhibitor in late-stage development with a positive European CHMP opinion. | Low |
| Moat | Any moat is hypothetical and depends on whether obicetrapib can win against statins, PCSK9 inhibitors, and bempedoic acid on efficacy, safety, convenience, and price. No commercial moat exists today. | Low |
| Management | Management has deep cardiovascular drug development experience, including founder and CSO John Kastelein and CEO Michael Davidson. The key test is executing the EC decision, US regulatory path, and any future commercial launch. | Low-medium |
| Financial trend | NAMS has minimal revenue and recurring operating losses. The most recent reported quarterly net loss was $48.44 million (Q1 March 2026). Cash and marketable securities were about $707.3 million at March 31, 2026, funding the pipeline for a period. | Medium |
| Valuation | At $3.17 billion market cap with almost no revenue, valuation is entirely based on probability-weighted peak sales and regulatory milestones for obicetrapib. This is a speculative biotech valuation. | Low |
| Technical trend | NAMS is in a short-term downtrend, trading near $27.11, below the 50-day moving average of about $32.29 and the 200-day moving average of about $33.85. The 52-week range is $21.14 to $42.21. | Medium |
| Risk level | Extremely high. Key risks: European Commission rejection or delay, US FDA rejection, PREVAIL outcomes trial failure, commercial adoption failure, cash burn and dilution, competition, binary catalyst gaps, and very high volatility. | Medium-high |
| AI confidence | Low confidence. AI tools can organize publicly available filings, price data, and analyst targets, but the NAMS outcome depends on future regulatory and clinical events that no model can predict. | Low data confidence |
| Investment certainty | Very low certainty. NAMS is appropriate only for high-risk-tolerant investors who understand biotech binary risk and use defined position sizing, because a single negative regulatory or trial outcome can cause a large loss. | Very low |
NAMS AI stock forecast
The NAMS AI stock forecast uses scenario ranges around the $27.11 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires a positive European Commission decision, US regulatory progress, positive PREVAIL interim data, and early commercial traction. The base case assumes approvals or data arrive but with delays or mixed results that keep the stock range-bound. The bearish case assumes regulatory rejection, trial failure, or financing difficulties.
$44 to $58
More likely if the European Commission grants marketing authorization in 2H26, US regulatory progress continues, the PREVAIL interim analysis at the end of 2026 is positive, and early European launches show traction. Analyst price targets cluster between about $45 and $60.
$27 to $40
More likely if the EC decision lands positively but commercial launch is slow, US regulatory timing is unclear, and the stock stays range-bound while the market waits for PREVAIL interim results in Q1 2027.
$16 to $24
More likely if the European Commission rejects or delays the application, the FDA issues a Complete Response Letter, PREVAIL misses at interim, cash runway concerns emerge, or competing therapies erode the commercial opportunity.
NAMS AI technical analysis
NAMS AI technical analysis starts from the $27.11 intraday price on August 3, 2026, and the July 31 close of $27.79. The stock is below its 50-day and 200-day moving averages, with RSI near 36, suggesting weak short-term momentum after a pullback from the $42 high. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $27.11 | Intraday price on August 3, 2026, with a previous close of $27.79 on July 31, 2026. |
| Near support | $26 to $27 | Recent pullback support zone. Biotech stocks can gap through levels on news. |
| Key support | $24 to $25 | The next major support area below the current pullback. A break would suggest a deeper sentiment shift. |
| Near resistance | $30 to $32 | The 50-day moving average near $32.29 is a key overhead level. A recovery needs sustained buying. |
| Key resistance | $33 to $34 | The 200-day moving average near $33.85 marks the upper end of the short-term recovery zone. |
| 52-week high | $42.21 | The 52-week high represents a resistance zone that would require a strong positive catalyst to retest. |
| 52-week low | $21.14 | The 52-week low is a potential extreme bear-case level if a negative catalyst hits. |
| Momentum | RSI near 36, below moving averages | RSI near 36 is weak but not yet oversold. Price is below both the 50-day and 200-day moving averages. |
| Volume | About 933K shares avg (20-day) | Average volume of about 933K shares per day. Recent sessions have not shown heavy accumulation. |
| Volatility | Very high, beta 0.08 | Beta is low due to limited correlation with the broad market, but actual daily moves can be large on regulatory or trial news. Size positions accordingly. |
| Short interest | 9.18 million shares, 9.22% of float | Short interest near 9.22% of shares outstanding adds squeeze and gap risk in either direction around catalysts. |
| Invalidation | Close below $26 or above $34 | A close below $26 weakens the near-term picture, while a close above $34 on volume would signal a recovery toward the moving averages. |
NAMS AI trading strategy
The NAMS AI trading strategy is a rules-based framework, not personalized advice. For pre-commercial biotech stocks, position size, catalyst timing, and invalidation levels are especially important because binary events such as the EC decision and PREVAIL interim analysis can cause large gaps.
Map the catalyst calendar: EC decision expected in 2H26, Q2 earnings on August 6, 2026, Investor Day on August 5, 2026, and PREVAIL interim analysis in Q4 2026 with results expected in Q1 2027. Define pre-event and post-event position plans before each date.
Never risk more than a defined small percentage of the portfolio on any single binary biotech event. Use options or defined-risk structures where appropriate.
With NAMS below its moving averages, a trader might wait for stabilization in the $26 to $32 zone before acting, buying near support with stops below the recent lows and targets near resistance.
Range trades in biotech can break violently on news. Stops should be wide enough to avoid noise but tight enough to limit gap risk.
Track the European Commission decision, US FDA interaction, PREVAIL interim timing, cash runway, financing activity, Menarini milestone payments, and analyst target changes. Also watch short interest and share dilution.
If cash runway shortens without a clear financing path, or if regulatory timelines slip repeatedly, reduce exposure.
Investment research summary
NewAmsterdam Pharma is developing obicetrapib, an oral CETP inhibitor aimed at lowering LDL cholesterol and cardiovascular risk, plus an obicetrapib/ezetimibe fixed-dose combination. The company has no approved product and only limited supply-agreement revenue so far.
There is no established moat. A positive European CHMP opinion on July 24, 2026 supports the clinical profile, but if approved, obicetrapib would still compete with statins, PCSK9 inhibitors, and bempedoic acid on efficacy, safety, convenience, and pricing.
The thesis can fail if the European Commission rejects or delays authorization, the FDA issues a Complete Response Letter, the PREVAIL outcomes trial misses at interim, or commercial adoption stalls. The company could also run out of cash and dilute shareholders.
The team, including founder and CSO John Kastelein and CEO Michael Davidson, has deep cardiovascular drug development experience. The open question is execution on regulatory strategy, the PREVAIL trial, and any future commercial launch.
Cardiovascular disease remains the leading cause of death globally, and a large population does not reach LDL-C goals on existing therapy. The market opportunity is real, but competition is intense and pricing pressure is significant.
At about $3.17 billion market cap with minimal revenue, the valuation reflects optimistic probability-adjusted peak sales and milestone assumptions for obicetrapib. There is no traditional margin of safety. The stock is a speculative bet on binary regulatory and trial outcomes.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NAMS price | $27.11 intraday on August 3, 2026 | StockAnalysis | August 3, 2026 |
| Market capitalization | $3.17 billion | StockAnalysis | August 3, 2026 |
| Shares outstanding | 116.90 million | StockAnalysis | August 3, 2026 |
| EPS (TTM) | -$1.78 | StockAnalysis | August 3, 2026 |
| 52-week range | $21.14 to $42.21 | StockAnalysis | August 3, 2026 |
| Revenue (TTM) | $22.57 million | StockAnalysis | August 3, 2026 |
| Net loss (TTM) | -$212.73 million | StockAnalysis | August 3, 2026 |
| Net loss (Q1 Mar 2026) | -$48.44 million | NewAmsterdam Q1 2026 press release | May 7, 2026 |
| Cash, cash equivalents and marketable securities (Mar 31, 2026) | $707.3 million | NewAmsterdam Q1 2026 press release | May 7, 2026 |
| Average analyst price target | $51.43 (range $37.20 to $60.81) | StockAnalysis forecast | July 27, 2026 |
| Analyst consensus | Strong Buy, 16 analysts (12 Strong Buy, 3 Buy, 1 Hold) | StockAnalysis forecast | July 27, 2026 |
| CHMP regulatory milestone | Positive CHMP opinion for Ubeslo and Evlarco on July 24, 2026 | NewAmsterdam press release | July 24, 2026 |
This NAMS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. NAMS is a pre-commercial biotechnology company with binary risk and high volatility.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
